vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and ESCO TECHNOLOGIES INC (ESE). Click either name above to swap in a different company.
ESCO TECHNOLOGIES INC is the larger business by last-quarter revenue ($289.7M vs $180.9M, roughly 1.6× AVANOS MEDICAL, INC.). ESCO TECHNOLOGIES INC runs the higher net margin — 9.9% vs -0.7%, a 10.6% gap on every dollar of revenue. On growth, ESCO TECHNOLOGIES INC posted the faster year-over-year revenue change (17.3% vs 0.7%). ESCO TECHNOLOGIES INC produced more free cash flow last quarter ($63.0M vs $21.3M). Over the past eight quarters, ESCO TECHNOLOGIES INC's revenue compounded faster (7.8% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Esco is a Singaporean brand that develops, manufactures, and sells products and services for laboratories.
AVNS vs ESE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $289.7M |
| Net Profit | $-1.3M | $28.7M |
| Gross Margin | 47.5% | 41.4% |
| Operating Margin | 1.4% | 13.2% |
| Net Margin | -0.7% | 9.9% |
| Revenue YoY | 0.7% | 17.3% |
| Net Profit YoY | 99.7% | 22.2% |
| EPS (diluted) | $-0.02 | $1.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $289.7M | ||
| Q3 25 | $177.8M | $286.5M | ||
| Q2 25 | $175.0M | $296.3M | ||
| Q1 25 | $167.5M | $265.5M | ||
| Q4 24 | $179.6M | $247.0M | ||
| Q3 24 | $170.4M | $298.5M | ||
| Q2 24 | $171.7M | $260.8M | ||
| Q1 24 | $166.1M | $249.1M |
| Q4 25 | $-1.3M | $28.7M | ||
| Q3 25 | $-1.4M | $218.7M | ||
| Q2 25 | $-76.8M | $26.1M | ||
| Q1 25 | $6.6M | $31.0M | ||
| Q4 24 | $-397.3M | $23.5M | ||
| Q3 24 | $4.3M | $34.3M | ||
| Q2 24 | $1.8M | $29.2M | ||
| Q1 24 | $-900.0K | $23.2M |
| Q4 25 | 47.5% | 41.4% | ||
| Q3 25 | 48.4% | 45.9% | ||
| Q2 25 | 52.6% | 41.2% | ||
| Q1 25 | 53.6% | 41.1% | ||
| Q4 24 | 54.6% | 39.8% | ||
| Q3 24 | 54.5% | 40.1% | ||
| Q2 24 | 55.7% | 39.6% | ||
| Q1 24 | 57.1% | 38.8% |
| Q4 25 | 1.4% | 13.2% | ||
| Q3 25 | 0.1% | 17.2% | ||
| Q2 25 | -42.6% | 11.2% | ||
| Q1 25 | 6.1% | 15.3% | ||
| Q4 24 | -233.0% | 11.4% | ||
| Q3 24 | 7.0% | 14.8% | ||
| Q2 24 | 3.7% | 14.3% | ||
| Q1 24 | 2.4% | 11.7% |
| Q4 25 | -0.7% | 9.9% | ||
| Q3 25 | -0.8% | 76.3% | ||
| Q2 25 | -43.9% | 8.8% | ||
| Q1 25 | 3.9% | 11.7% | ||
| Q4 24 | -221.2% | 9.5% | ||
| Q3 24 | 2.5% | 11.5% | ||
| Q2 24 | 1.0% | 11.2% | ||
| Q1 24 | -0.5% | 9.3% |
| Q4 25 | $-0.02 | $1.11 | ||
| Q3 25 | $-0.03 | $8.43 | ||
| Q2 25 | $-1.66 | $1.01 | ||
| Q1 25 | $0.14 | $1.20 | ||
| Q4 24 | $-8.64 | $0.91 | ||
| Q3 24 | $0.09 | $1.32 | ||
| Q2 24 | $0.04 | $1.13 | ||
| Q1 24 | $-0.02 | $0.90 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $103.8M |
| Total DebtLower is stronger | $90.3M | $145.5M |
| Stockholders' EquityBook value | $778.2M | $1.6B |
| Total Assets | $1.1B | $2.4B |
| Debt / EquityLower = less leverage | 0.12× | 0.09× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $103.8M | ||
| Q3 25 | $70.5M | $101.3M | ||
| Q2 25 | $90.3M | $78.7M | ||
| Q1 25 | $97.0M | $57.4M | ||
| Q4 24 | $107.7M | $71.3M | ||
| Q3 24 | $89.0M | $66.0M | ||
| Q2 24 | $92.2M | $63.0M | ||
| Q1 24 | $75.8M | $59.4M |
| Q4 25 | $90.3M | $145.5M | ||
| Q3 25 | $93.4M | $186.0M | ||
| Q2 25 | $95.7M | $525.0M | ||
| Q1 25 | $98.0M | $88.0M | ||
| Q4 24 | $125.3M | $112.0M | ||
| Q3 24 | $152.6M | $122.0M | ||
| Q2 24 | $164.9M | $173.0M | ||
| Q1 24 | $167.2M | $191.0M |
| Q4 25 | $778.2M | $1.6B | ||
| Q3 25 | $778.0M | $1.5B | ||
| Q2 25 | $776.3M | $1.3B | ||
| Q1 25 | $839.4M | $1.3B | ||
| Q4 24 | $828.5M | $1.2B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.2B | $1.2B |
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $1.0B | $2.5B | ||
| Q1 25 | $1.1B | $1.8B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $1.7B | $1.8B | ||
| Q2 24 | $1.7B | $1.8B | ||
| Q1 24 | $1.7B | $1.8B |
| Q4 25 | 0.12× | 0.09× | ||
| Q3 25 | 0.12× | 0.12× | ||
| Q2 25 | 0.12× | 0.40× | ||
| Q1 25 | 0.12× | 0.07× | ||
| Q4 24 | 0.15× | 0.09× | ||
| Q3 24 | 0.12× | 0.10× | ||
| Q2 24 | 0.13× | 0.14× | ||
| Q1 24 | 0.14× | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $68.9M |
| Free Cash FlowOCF − Capex | $21.3M | $63.0M |
| FCF MarginFCF / Revenue | 11.8% | 21.7% |
| Capex IntensityCapex / Revenue | 3.8% | 2.0% |
| Cash ConversionOCF / Net Profit | — | 2.40× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $239.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $68.9M | ||
| Q3 25 | $14.0M | $109.9M | ||
| Q2 25 | $6.8M | $73.7M | ||
| Q1 25 | $25.7M | $24.1M | ||
| Q4 24 | $57.9M | $34.2M | ||
| Q3 24 | $23.0M | $72.1M | ||
| Q2 24 | $27.8M | $36.2M | ||
| Q1 24 | $-8.0M | $10.5M |
| Q4 25 | $21.3M | $63.0M | ||
| Q3 25 | $7.0M | $97.8M | ||
| Q2 25 | $-4.2M | $64.9M | ||
| Q1 25 | $19.0M | $14.0M | ||
| Q4 24 | $53.1M | $29.0M | ||
| Q3 24 | $20.0M | $60.9M | ||
| Q2 24 | $21.9M | $27.6M | ||
| Q1 24 | $-12.1M | $2.0M |
| Q4 25 | 11.8% | 21.7% | ||
| Q3 25 | 3.9% | 34.1% | ||
| Q2 25 | -2.4% | 21.9% | ||
| Q1 25 | 11.3% | 5.3% | ||
| Q4 24 | 29.6% | 11.7% | ||
| Q3 24 | 11.7% | 20.4% | ||
| Q2 24 | 12.8% | 10.6% | ||
| Q1 24 | -7.3% | 0.8% |
| Q4 25 | 3.8% | 2.0% | ||
| Q3 25 | 3.9% | 4.2% | ||
| Q2 25 | 6.3% | 3.0% | ||
| Q1 25 | 4.0% | 3.8% | ||
| Q4 24 | 2.7% | 2.1% | ||
| Q3 24 | 1.8% | 3.8% | ||
| Q2 24 | 3.4% | 3.3% | ||
| Q1 24 | 2.5% | 3.4% |
| Q4 25 | — | 2.40× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 2.83× | ||
| Q1 25 | 3.89× | 0.78× | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | 5.35× | 2.10× | ||
| Q2 24 | 15.44× | 1.24× | ||
| Q1 24 | — | 0.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
